Cost-effectiveness of HIV screening in acute care settings

Archives of Internal Medicine

Volumn 156, Issue 4, 1996, Pages 394-404

  Owens, Douglas K ^a,b   Nease Jr , Robert F ^c   Harris, Ryan A ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG ABUSE; EARLY DIAGNOSIS; FEMALE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COUNSELING; PRIORITY JOURNAL; QUALITY OF LIFE; SCREENING; SEXUAL BEHAVIOR; TREATMENT OUTCOME; VIRUS TRANSMISSION;

ACUTE DISEASE; ADOLESCENT; ADULT; COST-BENEFIT ANALYSIS; CRITICAL CARE; DECISION MAKING; FEMALE; HIV INFECTIONS; HIV SEROPREVALENCE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; RISK FACTORS; RISK-TAKING; SENSITIVITY AND SPECIFICITY; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0030025261     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.4.394     Document Type: Article

References (104)

1. Centers for Disease Control and Prevention. Update: mortality attributable to HIV infection among persons aged 25-44 years - United States, 1991 and 1992. MMWR Morb Mortal Wkly Rep. 1993;42:869-872.
2. Centers for Disease Control and Prevention Recommendations for HIV testing services for inpatients and outpatients in acute-care hospital settings MMWR Morb Mortal Wkly Rep. 1993;42(RR-2):1-6.
3. Janssen R, St Louis M, Satten G, et al HIV infection among patients in US acute care hospitals: strategies for the counseling and testing of the hospital patients. N Engl J Med 1992,327:445-452
4. Lurie P, Avins A, Phillips K, Kahn J, Lowe R, Ciccarone D The cost-effectiveness of voluntary counseling and testing of hospital inpatients for HIV infection. JAMA. 1994;272:1832-1838.
5. Harris R, Boisaubin E, Salyer P, Semands D. Evaluation of a hospital admission HIV antibody voluntary screening program. Infect Control Hosp Epidemiol 1990,11 628-634
6. Henry K, Campbell S. The potential efficiency of routine HIV testing of hospital patients data from a CDC sentinel hospital. Public Health Rep. 1992, 107:138-141.
7. McCarthy BD, Wong JB, Munoz A, Sonnenberg FA Who should be screened for HIV infection? a cost-effectiveness analysis. Arch Intern Med. 1993,153: 1107-1116.
8. Owens DK, Harris RA, Scott PM, Nease RF. Screening surgeons for human immunodeficiency virus (HIV) a cost-effectiveness analysis Ann Intern Med 1995;122 641-652.
9. Owens DK, Nease RF, Harris RA. Screening for HIV infection in acute-care settings determinants of cost-effectiveness Med Decis Making 1993;13: 395. Abstract
10. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983,3 419-458.
11. Owens DK, Nease RF. Occupational exposure to human immunodeficiency virus and hepatitis B virus: a comparative analysis of risk Am J Med 1992, 92:503-512.
12. Owens DK, Nease RF Transmission of human immunodeficiency virus (HIV) infection between physicians and patients a model-based analysis of risk. In: Kaplan E, Brandeau ML, eds Modeling the AIDS Epidemic: Planning, Policy, and Prediction New York, NY: Raven Press; 1994 153-177.
13. Longini IJ, Clark WS, Byers RH, et al Statistical analysis of the stages of HIV infection using a Markov model Stat Med. 1989;8:831-843.
14. St Louis M, Rauch KJ, Petersen LR, Anderson JE, Schable CA, Dondero TJ. Seroprevalence rates of human immunodeficiency virus infection at sentinel hospitals in the United States: The Sentinel Hospital Surveillance Group. N Engl J Med 1990,323 213-218
15. Padian N Marquis L, Francis DP, et al Male-to-female transmission of human immunodeficiency virus. JAMA. 1987;258 788-790.
16. Padian NS. Sexual histories of heterosexual couples with one HIV-infected partner. Am J Public Health. 1990,80:990-991.
17. Padian NS, Shiboski SC, Jewell NP. Female-to-male transmission of human immunodeficiency virus. JAMA. 1991;266.1664-1667
18. Wood FW. An American Profile: Opinions and Behavior, 1972-1989 Detroit, Mich: Gale Research; 1990.
19. Hunt AJ, Davies PM, Weatherburn P, Coxon AP, McManus TJ. Sexual partners, penetrative sexual partners and HIV risk. AIDS. 1991,5.723-728.
20. Smith TW Adult sexual behavior in 1989: number of partners, frequency of intercourse and risk of AIDS Fam Plann Perspect 1991,23 102-107
21. Billy JO, Tanfer K, Grady WR, Klepinger DH. The sexual behavior of men in the United States Fam Plann Perspect. 1993;25:52-60.
22. DeBuono BA, Zinner SH, Daamen M, McCormack WM. Sexual behavior of college women in 1975, 1986, and 1989. N Engl J Med. 1990;322:821-825.
23. Forman D, Chilvers C. Sexual behaviour of young and middle aged men in England and Wales BMJ 1989,298.1137-1142
24. Higgins DL, Galavotti C, O'Reilly KR, et al. Evidence for the effects of HIV antibody counseling and testing on risk behaviors. JAMA 1991,266:2419-2429.
25. Wenger NS, Linn LS, Epstein M, Shapiro MF. Reduction of high-risk sexual behavior among heterosexuals undergoing HIV antibody testing: a randomized clinical trial. Am J Public Health 1991;81 1580-1585.
26. Kamenga M. Condom use and associated HIV seroconversion following intensive HIV counseling of 122 married couples in Zaire with discordant HIV serology. In: Proceedings and Abstracts of the Fifth International Conference on AIDS, June 4-9, 1989, Montreal, Quebec Ottawa, Ontario: International Development Research Centre; 1989;1:703
27. Calsyn DA, Saxon AJ, Freeman GJ, Whittaker S. Ineffectiveness of AIDS education and HIV antibody testing in reducing high-risk behaviors among injection drug users Am J Public Health. 1992;82:573-575.
28. Wenger NS, Greenberg JM, Hilborne LH, Kusseling F, Mangotich M, Shapiro MF. Effect of HIV antibody testing and AIDS education on communication about HIV risk and sexual behavior, a randomized, controlled trial in college students. Ann Intern Med 1992,117:905-911.
29. McCusker J, Stoddard AM, Mayer KH, Zapka J, Morrison C, Saltzman SP. Effects of HIV antibody test knowledge on subsequent sexual behaviors in a cohort of homosexually active men Am J Public Health. 1988;78:462-467.
30. Lindan C. HIV testing and education promote safer sex among urban women in Rwanda. In: Proceedings and Abstracts of the Sixth International Conference on AIDS, June 20-24, 1990; San Fransisco, Calif. San Francisco. University of California: 1990,3.256.
31. Sonenstein FL, Pleck JH, Ku LC. Sexual activity, condom use and AIDS awareness among adolescent males Fam Plann Perspect. 1989;21:152-158
32. Hardy WD, Feinberg J, Finkelstein DM, et al A controlled trial of trimethoprimsulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome N Engl J Med 1992,327 1842-1848.
33. Buira E, Gatell JM, Miro JM, et al. Influence of treatment with zidovudine (ZDV) on the long-term survival of AIDS patients J Acquir Immune Defic Syndr. 1992.5:737-742
34. Lemp GF, Payne SF, Neal D, Temelso T, Rutherford GW. Survival trends for patients with AIDS. JAMA 1990;263:402-406.
35. Vella S, Giuliano M, Pezzotti P, et al. Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. JAMA. 1992;267.1232-1236
36. Fischl MA, Parker CB, Pettinelli C, et al A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1990;323:1009-1014.
37. Garcia A, Bischofberger C, Gutierrez E, Navarro C Survival patterns with AIDS cases in the southeast of Spain In: Proceedings and Abstracts of the Eighth International Conference on AIDS, July 19-24, 1992, Amsterdam, the Netherlands. Amsterdam, the Netherlands: CONGREX Holland BV, 1992;2:C348
38. AIDS Registry Group of Madrid. Long-term survival of AIDS patients in Madrid In: Proceedings and Abstracts of the Eighth International Conference on AIDS; July 19-24, 1992; Amsterdam, the Netherlands. Amsterdam, the Netherlands CONGREX Holland BV; 1992,2:C348.
39. Moore RD, Hidalgo J, Sugland BW, Chaisson RE. Zidovudine and the natural history of the acquired immunodeficiency syndrome N Engl J Med. 1991, 324.1412-1416.
40. Fischl MA, Richman DD, Hansen N, et al The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind, placebo-controlled trial. Ann Intern Med. 1990,112 727-737.
41. Volberding PA, Lagakos SW, Koch MA, et al Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med. 1990; 322:941-949.
42. Hamilton JD Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection results of the Veterans Affairs Cooperative Study. N Engl J Med. 1992;326:437-443.
43. Aboulker JP, Swart AM. Preliminary analysis of the Concorde trial: Concorde Coordinating Committee. Lancet 1993;341 889-890.
44. Graham NM, Zeger SL, Park LP, et al. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. Lancet. 1991;338.265-269.
45. Graham NM, Zeger SL, Park LP, et al. The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med. 1992;326: 1037-1042
46. McLeod GX, Hammer SM. Zidovudine. five years later. Ann Intern Med. 1992; 117:487-501
47. Vittecoq D, Lefrere JJ Poor long-term efficacy of zidovudine in early HIV infection. In. Proceedings and Abstracts of the Eighth International Conference on AIDS, July 19-24, 1992, Amsterdam, the Netherlands. Amsterdam, the Netherlands: CONGREX Holland BV, 1892,3:145.
48. Masur H. Prevention and treatment of Pneumocystis pneumonia. N Engl J Med. 1992;327.1853-1860.
49. Schneider MM, Hoepelman AI, Eeftinck SJK, et al A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992,327:1836-1841.
50. Hellinger FJ. Forecasts of the costs of medical care for persons with HIV: 1992-1995 Inquiry. 1992;29:356-365.
51. Hellinger F. The lifetime cost of treating a person with HIV. JAMA 1993;270: 474-478.
52. Andrulis DP, Weslowski VB, Hintz E, Spolarich AW. Comparisons of hospital care for patients with AIDS and other HIV-related conditions JAMA. 1992; 267.2482-2486.
53. Arno PS, Shenson D, Siegel NF, Franks P, Lee PR. Economic and policy implications of early intervention in HIV disease. JAMA. 1989,262:1493-1498.
54. Bennett CL, Pascal A, Cvitanic M, Graham V, Kitchens A, DeHovitz JA Medical care costs of intravenous drug users with AIDS in Brooklyn. J Acquir Immune Defic Syndr 1992,5.1-6.
55. Campbell LS, Stein J, Fondren LK, et al. Inpatients with AIDS and AIDS-related complex: economic impact on hospitals in North Carolina South Med J. 1991;84:22-26.
56. Hiatt RA, Quesenberry CJ, Selby JV, Fireman BH, Knight A The cost of acquired immunodeficiency syndrome in Northern California, the experience of a large prepaid health plan. Arch Intern Med. 1990;150 833-838
57. Hahn B, Lefkowitz D. Annual Expenses and Sources of Payment for Health Care Services. Rockville, Md. Agency for Health Care Policy and Research, 1992.
58. US Bureau of the Census. Statistical Abstract of the United States 1992. Washington, DC: US Government Printing Office; 1992
59. Owens DK, Nease RF. Physician beliefs about occupational risk and severity of health states associated with HIV and hepatitis infection In: Proceedings and Abstracts of the Sixth International Conference on AIDS; June 20-24, 1990; San Francisco, Calif. San Francisco: University of California; 1990,3 308
60. Schwartz JS, Kinosian BP, Pierskalla WP, Lee H. Strategies for screening blood for human immunodeficiency virus antibody: use of a decision support system JAMA. 1990;264.1704-1710
61. Centers for Disease Control and Prevention Update: serologic testing for HIV-1 antibody - United States, 1988 and 1989. MMWR Morb Mortal Wkly Rep. 1990;39:380-383
62. MacDonald KL, Jackson JB, Bowman RJ, et al Performance characteristics of serologic tests for human immunodeficiency virus type 1 (HIV-1) antibody among Minnesota blood donors: public health and clinical implications Ann Intern Med. 1989;110:617-621
63. Jewett JF, Hecht FM Preventive health care for adults with HIV infection JAMA. 1993,269.1144-1153.
64. Goedert JJ, Kessler CM, Aledort LM, et al A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med. 1989;321:1141-1148.
65. Russell LB. Some of the tough decisions required by a national health plan. Science. 1989,246:892-896.
66. El-Sadr W, Oleske JM, Agins BD, et al. Evaluation and Management of Early HIV Infection: Clinical Practice Guideline No. 7. Rockville, Md. Agency for Health Care Policy and Research, 1994 US Dept of Health and Human Services publication PHS 94-0572
67. Lundgren JD, Phillips AN, Pedersen C et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. JAMA. 1994;271:1088-1092.
68. Osmond D, Charlebois E, Lang W, Shiboski S, Moss A Changes in AIDS survival time in two San Francisco cohorts of homsexual men, 1983-1993. JAMA 1994;271:1083-1087
69. Fischl MA, Dickinson GM, La VL. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA. 1988;259:1185-1189.
70. Owens DK, Sox HC Medical decision making: probabilistic medical reasoning. In: Shortliffe EH, Perreault LE, Fagan LM, Wiederhold G, eds Medical Informatics Computer Applications in Medicine. Reading, Mass. Addison-Wesley Publishing Co; 1990:70-116
71. Sanders GD, Owens DK, Padian N, Cardinalli AB, Sullivan AN, Nease RF. A computer-based interview to identify HIV risk behaviors and to assess patient preferences for HIV-related health states. In: Proceedings of the Annual Symposium on Computer Applications in Medical Care: Washington, DC. Philadelphia. Pa Hanley & Belfus Inc, 1994,1:20-24
72. Sox HC, Blatt MA, Higgins MC, Marion KI. Decision making when the outcomes have several dimensions In Medical Decision Making. Stoneham, Mass: Butterworths, 1988 201-236.
73. Valdiserri RO, Lyter D, Leviton LC, Callahan CM, Kingsley LA, Rinaldo CR Variables influencing condom use in a cohort of gay and bisexual men. Am J Public Health. 1988;78:801-805.
74. Ku LC, Sonenstein FL, Pleck JH. The association of AIDS education and sex education with sexual behavior and condom use among teenage men Fam Plann Perspect 1992;24:100-106.
75. Ickovics J, Morrill A, Beren S, Walsh U, Rodin J. Limited effects of HIV counseling and testing for women. JAMA. 1994;272.443-448
76. Battjes RJ, Pickens RW, Amsel Z HIV infection and AIDS risk behaviors among intravenous drug users entering methadone treatment in selected US cities J Acquir Immune Defic Syndr. 1991;4:1148-1154
77. Battjes RJ, Pickens RW, Haverkos HW, Sloboda Z. HIV risk factors among injecting drug users in five US cities AIDS. 1994;8:681-687.
78. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Atlanta, Ga. Centers for Disease Control and Prevention; 1993;5:6.
79. Battjes RJ, Pickens RW, Amsel Z, Brown LS Jr. Heterosexual transmission of human immunodeficiency virus among intravenous drug users. J Infect Dis 1990 162:1007-1011.
80. Kaplan EH, Heimer R. A model-based estimate of HIV infectivity via needle sharing J Acquir Immune Defic Syndr 1992;5:1116-1118.
81. Watters JK, Cheng Y-T. Toward comprehensive studies of HIV in intravenous drug users: issues in treatment-based and street-based samples NIDA Res Monogr 1991;109:63-73.
82. Vanichseni S, Choopanya K, Des Jarlais DC, et al HIV testing and sexual behavior among intravenous drug users in Bangkok, Thailand. J Acquir Immune Defic Syndr. 1992;5:1119-1123.
83. Van den Hoek JAR, van Haastrecht HA, Coutinho RA. Little change in sexual behavior in injecting drug users in Amsterdam. J Acquir Immune Defic Syndr. 1992,5:518-522.
84. Des Jarlais DC, Choopanya K, Vanicheseni S, et al. AIDS risk reduction and reduced HIV seroconversion among injection drug users in Bangkok. Am J Public Health. 1994;84:452-455.
85. Van Ameijden EJC, van den Hoek AAR, Coutinho RA. Injecting risk behavior among drug users in Amsterdam, 1986 to 1992, and its relationship to AIDS prevention programs. Am J Public Health. 1994;84:275-281.
86. Stephens RC, Feucht TE, Roman SW. Effects of an intervention program on AIDS-related drug and needle behavior among intravenous drug users. Am J Public Health. 1991;81:568-571.
87. El-Bassel N, Schilling RF 15-month followup of women methadone patients taught skills to reduce heterosexual HIV transmission. Public Health Rep 1992, 107:500-504
88. Hedlund K, Spencer J, Schall W, Johnson L, Fend K. Estimated public costs of HIV counseling and testing. In: Proceedings and Abstracts of the Sixth International Conference on AIDS, June 20-24, 1990; San Francisco, Calif San Francisco: University of California, 1990;2:290
89. Brandeau ML, Owens DK. When women return to risk: costs and benefits of HIV screening in the presence of relapse. In: Kaplan EH, Brandeau ML, eds. Modeling the AIDS Epidemic: Planning, Policy and Prediction. New York, NY: Raven Press: 1994.121-136.
90. Eddy D. Screening for lung cancer. Ann Intern Med. 1989,111:232-237.
91. Eddy D Screening for breast cancer. Ann Intern Med. 1989;111:389-399.
92. Eddy D Screening for cervical cancer. Ann Intern Med. 1990;113:214-226.
93. Littenberg B, Garber AM, Sox HJ. Screening for hypertension. Ann Intern Med 1990,112 192-202
94. Laupacis A, Feeny D, Detsky A, Tugwell P. How attractive does a new technology have to be to warrant adoption and utilization? tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146:473-481.
95. Laupacis A Feeny D, Detsky A, Tugwell P. Tentative guidelines for using clinical and economic evaluations revisited. Can Med Assoc J. 1993;148:927-929
96. Naylor C, Williams J, Basinski A, Goel V. Technology assessment and cost-effectiveness analysis: misguided guidelines? Can Med Assoc J. 1993;148:921-924.
97. Gafni A, Birch S Guidelines for the adoption of new technologies a prescription for uncontrolled growth in expenditures and how to avoid the problem Can Med Assoc J. 1993 148:913-917.
98. Lenderking WR, Gelber RD, Cotton DJ, et al Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 1994;330.738-743
99. Brandeau ML, Owens DK, Sox CH, Wachter RM. Screening women of child-bearing age for human immunodeficiency virus, a cost-benefit analysis. Arch Intern Med 1992,152 2229-2237.
100. Brandeau ML, Owens DK, Sox CH, Wachter RW. Screening women of child-bearing age for human immunodeficiency virus infection: a model-based policy analysis. Manage Sci. 1993;39.72-92
101. Adib SM, Joseph JG, Ostrow DG, Tal M Schwartz SA Relapse in sexual behavior among homosexual men a 2-year folluw-up from the Chicago MACS/ CCS. AIDS 1991,5.757-760
102. McCusker J, Stoddard A, McDonald M, Zapka J, Mayer K. Maintenance of behavioral change in a cohort of homosexually active men AIDS. 1992,6:861-868.
103. McKusick L, Coates T, Morin S, Pollack L, Hoff C. Longitudinal predictors of reductions in unprotected anal intercourse among gay men in San Francisco, the AIDS Behavioral Research Project. Am J Public Health 1990;80:978-983.
104. Stall R, Ekstrand M, Pollack L, McKusick L, Coates TJ. Relapse from safer sex: the next challenge for AIDS prevention efforts J Acquir Immune Defic Syndr 1990,3.1181-1187.